-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Incyte delivered robust Q1 2026 results with total revenue of $1.27B (+21% Y/Y) and net sales of $1.10B (+20% Y/Y), significantly above expectations. Strong performance was driven by effective commercial execution across the diversified portfolio, with Jakafi maintaining momentum at $758M (+7% Y/Y) and Opzelura continuing impressive growth at $143M (+20% Y/Y). We view the exceptional hematology and oncology portfolio growth of $204M (+116% Y/Y), led by Niktimvo, Monjuvi, and Zynyz, as a critical strategic diversification beyond Jakafi ahead of the 2029 patent cliff. The company reaffirmed full-year 2026 guidance across all categories, expecting total net sales of $4.77B-$4.94B. We believe Incyte's advanced pipeline, with 10 Phase 3 studies including positive povorcitinib results in vitiligo and the pivotal DAWN-303 KRASG12D inhibitor trial, positions the company well for long-term growth under CEO Bill Meury's strategic focus on high-potential assets.